Table 10.
The evaluation of the anticancer properties of ligand (HL) and its complexes (1a-2a) against cancer cell lines and normal cell lines.
| Compounds | IC50 (μM) | |||
|---|---|---|---|---|
| A549 | HepG2 | MCF-7 | NHDF | |
| Cisplatin | 31.9 ± 1.6 | 22.9 ± 1.1 | 20.2 ± 1.0 | 26.9 ± 1.3 |
| (HL) | 126.4 ± 6.3 | 108.4 ± 5.4 | 105.2 ± 5.3 | 208.6 ± 10.4 |
| (1a) | 30.8 ± 1.5 | 33.1 ± 1.7 | 32.1 ± 1.6 | 73.6 ± 3.7 |
| (2a) | 34.3 ± 1.7 | 34.6 ± 1.7 | 35.6 ± 1.8 | 78.4 ± 3.9 |